Pure Global AI
NCT06299696Completed

A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

A Phase 1, Open-label Taste Assessment Study of Vanzacaftor/Tezacaftor/Deutivacaftor in Healthy Adult Panelists
Vertex Pharmaceuticals IncorporatedPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Cystic Fibrosis
Drug/Device/Intervention
VNZ/TEZ/D-IVA
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Vertex Pharmaceuticals Incorporated
Location
Woburn, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Mar 26, 2024
End date
Apr 16, 2024
Enrollment
10 participants
Primary outcome

Flavor Assessment Based on Flavor Profile Method of Descriptive Sensory Analysis per American Society for Testing and Material (ASTM) Approved Sensory Evaluation Method

Summary

The purpose of this study is to evaluate the flavor (basic tastes, aroma, texture, mouthfeel)
 of VNZ/TEZ/D-IVA fixed dose combination (FDC) granules.

ICD-10 classifications
Cystic fibrosisCystic fibrosis, unspecifiedCystic fibrosis with other manifestationsCystic fibrosis with pulmonary manifestationsCystic fibrosis with intestinal manifestations
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06299696
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06299696 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently Completed. The study focuses on Cystic Fibrosis. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.